Test may help physicians identify effective treatment earlier MALVERN, Pennsylvania and ABBOTT PARK, Illinois, January 27 (HSMN NewsFeed) — Fujirebio Diagnostics, Inc. and Abbott have signed a license agreement to develop a new ovarian cancer test fo…
Diagnostics, Oncology
Fujirebio Diagnostics, Abbott, HE4 biomarker, ovarian cancer

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Fujirebio Diagnostics and Abbott Agree To Develop New Ovarian Cancer Test for Abbott s Architect(R) Analyzers”
Leave a Comment